Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.58 |
| ▸ | LMNA | P02545 | 8/20 | 0.58 |
| ▸ | HTT | P42858 | 7/20 | 0.54 |
| ▸ | NR2F2 | P24468 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2840809 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAHTTNR2F2RAB9A | |
| SCHEMBL3431144 | 0.79 | CA2 (0.64) | SMN1; SMN2LMNAHTTNR2F2RAB9A | |
| SCHEMBL229506 | 0.78 | CA12 (0.68) | LMNAHTTALDH1A1L3MBTL1CA2 | |
| SCHEMBL6138556 | 0.78 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAHTTNR2F2RAB9A | |
| SCHEMBL5652939 | 0.77 | CYP1A2 (0.58) | ALDH1A1 | |
| Water SCHEMBL3952740 | 0.77 | CA12 (0.65) | LMNAHTTALDH1A1L3MBTL1CA2 | |
| Ammonia Solution, Strong SCHEMBL4593139 | 0.77 | CA12 (0.65) | LMNAHTTALDH1A1L3MBTL1CA2 | |
| SCHEMBL10953887 | 0.77 | CA12 (0.65) | LMNAHTTALDH1A1L3MBTL1CA2 | |
| SCHEMBL3194925 | 0.76 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAHTTNR2F2RAB9A | |
| SCHEMBL22690487 | 0.75 | CA2 (0.56) | ALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1693372-A1 | Novel Sulfamides and their use as endothelin receptor antagonists | Actelion Pharmaceuticals Ltd. (CH) | 2006-08-23 | — | — | EP | claimed |
| US-7094781-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-22 | — | — | US | claimed |
| EP-1345920-B1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-12 | — | — | EP | claimed |
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | US | claimed |
| EP-1345920-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2003-09-24 | — | — | EP | claimed |
| WO-2002053557-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-07-11 | — | — | WO | claimed |
| US-4952397-A | HAVING PYRIDINIUM GROUP; ADMINISTERED WITH A DEHYDROPEPTIDASE INHIBITOR | MERCK & CO., INC. (US) | 1990-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | SMN1; SMN2 2976/4885LMNA 3135/4885HTT 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.